- Home
- PBYI vs FT Comparison
PBYI vs FT Comparison
Compare PBYI & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- FT
- Stock Information
- Founded
- PBYI 2010
- FT 1988
- Country
- PBYI United States
- FT United States
- Employees
- PBYI N/A
- FT N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- FT Trusts Except Educational Religious and Charitable
- Sector
- PBYI Health Care
- FT Finance
- Exchange
- PBYI Nasdaq
- FT Nasdaq
- Market Cap
- PBYI 153.2M
- FT 185.7M
- IPO Year
- PBYI N/A
- FT N/A
- Fundamental
- Price
- PBYI $3.09
- FT $7.29
- Analyst Decision
- PBYI Strong Buy
- FT
- Analyst Count
- PBYI 1
- FT 0
- Target Price
- PBYI $7.00
- FT N/A
- AVG Volume (30 Days)
- PBYI 754.5K
- FT 63.0K
- Earning Date
- PBYI 02-27-2025
- FT 01-01-0001
- Dividend Yield
- PBYI N/A
- FT 7.85%
- EPS Growth
- PBYI 492.79
- FT N/A
- EPS
- PBYI 0.47
- FT N/A
- Revenue
- PBYI $243,569,000.00
- FT N/A
- Revenue This Year
- PBYI N/A
- FT N/A
- Revenue Next Year
- PBYI N/A
- FT N/A
- P/E Ratio
- PBYI $6.63
- FT N/A
- Revenue Growth
- PBYI 6.30
- FT N/A
- 52 Week Low
- PBYI $2.23
- FT $5.97
- 52 Week High
- PBYI $7.73
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- PBYI 49.17
- FT 40.30
- Support Level
- PBYI $2.92
- FT $7.19
- Resistance Level
- PBYI $4.06
- FT $7.35
- Average True Range (ATR)
- PBYI 0.29
- FT 0.09
- MACD
- PBYI 0.01
- FT 0.00
- Stochastic Oscillator
- PBYI 27.07
- FT 43.75
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.